Alpha Cognition's ZUNVEYL: Q4 & Full Year 2025 Earnings
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Alpha Cognitions Q4 and full year 2025 earnings showcase strong momentum for their Alzheimers drug ZUNVEYL, the first new oral treatment in over fifteen years. Net product sales reached $2.5 million in Q4, pushing total revenue to $2.8 million, and full year sales hit $6.8 million out of $10.2 million total. They dispensed nearly 5,000 bottles in Q4, with December being their best month yet. Demand is growing in long-term care, with nearly 2,000 nursing homes using ZUNVEYL, and prescribing doctors increased by 50% from last quarter. They secured a second national PBM contract, covering two of the top four, and expanded their sales team and peer education. Cash stands at $66 million, debt-free, funding operations into 2027. Theyre launching three real-world studies this year and advancing a sublingual version for swallowing issues. With payer wins, study data, and sales push, Alpha Cognition is building toward operational profitability in 2027.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/75b045af3ce4d56d